Literature DB >> 32613680

Clinical characteristics, genetics, comorbidities and treatment of palmoplantar pustulosis: A retrospective analysis of 66 cases in a single center in Taiwan.

Chang-Ming Huang1, Tsen-Fang Tsai2.   

Abstract

We retrospectively analyzed 66 patients with palmoplantar pustulosis (PPP) from January 1994 to September 2019 in our department. Interleukin-36 receptor antagonist gene (IL36RN) intron 3 c.115+6T>C mutation was present in two out of 27 patients (7.4%). Both cases developed generalized pustular psoriasis and/or acrodermatitis continua of Hallopeau later. Topical medications and phototherapy were used in 93.9% and 28.8% of patients, respectively, while 60.6% received systemic agents. The majority of patients (60.6%) responded to treatment, but episodes of flare-up existed. The demographic data of our patients with PPP showed female predominance (59.1%), middle-age onset (44.2 years old) and current smokers (62.1%). Generalized pustular psoriasis initially presenting as palmoplantar lesions may be misdiagnosed as PPP, and the presence of IL36RN mutation may serve to predict or confirm the diagnosis of future generalized pustular psoriasis or acrodermatitis continua of Hallopeau. To our knowledge, this is the largest demographic study of PPP in Taiwan.
© 2020 Japanese Dermatological Association.

Entities:  

Keywords:  zzm321990IL36RNzzm321990; CARD14; Taiwanese; palmoplantar pustulosis; psoriasis

Mesh:

Substances:

Year:  2020        PMID: 32613680     DOI: 10.1111/1346-8138.15470

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  2 in total

1.  Risks of Comorbidities in Patients With Palmoplantar Pustulosis vs Patients With Psoriasis Vulgaris or Pompholyx in Korea.

Authors:  Dong Hyo Kim; Jin Yong Lee; Soo Ick Cho; Seong Jin Jo
Journal:  JAMA Dermatol       Date:  2022-06-01       Impact factor: 11.816

2.  Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort.

Authors:  F Assan; B Husson; S Hegazy; J Seneschal; F Aubin; E Mahé; D Jullien; E Sbidian; M D'Incan; C Conrad; E Brenaut; C Girard; M A Richard; H Bachelez; M Viguier
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-04-12       Impact factor: 9.228

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.